Several studies have reported that phosphorylation of Akt at Thr308 serves as a marker of an aggressive phenotype and poor prognosis, particularly in AML patients, as its activation contributes to chemotherapy resistance [44]. The gene discussed is AKT1; the disease is acute myeloid leukemia.